NFJ Investment Group LLC Takes $3.89 Million Position in BioMarin Pharmaceutical Inc. $BMRN

NFJ Investment Group LLC acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the second quarter, HoldingsChannel reports. The firm acquired 67,991 shares of the biotechnology company’s stock, valued at approximately $3,890,000.

A number of other large investors have also added to or reduced their stakes in BMRN. Rice Hall James & Associates LLC bought a new stake in BioMarin Pharmaceutical during the 2nd quarter worth approximately $14,203,000. Swedbank AB raised its stake in shares of BioMarin Pharmaceutical by 70.6% during the fourth quarter. Swedbank AB now owns 796,737 shares of the biotechnology company’s stock valued at $47,350,000 after acquiring an additional 329,794 shares during the last quarter. LSV Asset Management raised its stake in shares of BioMarin Pharmaceutical by 4.3% during the fourth quarter. LSV Asset Management now owns 882,200 shares of the biotechnology company’s stock valued at $52,429,000 after acquiring an additional 36,700 shares during the last quarter. C WorldWide Group Holding A S lifted its holdings in shares of BioMarin Pharmaceutical by 12.6% during the fourth quarter. C WorldWide Group Holding A S now owns 267,851 shares of the biotechnology company’s stock worth $15,918,000 after purchasing an additional 30,000 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in shares of BioMarin Pharmaceutical during the second quarter worth $944,000. Institutional investors own 98.71% of the company’s stock.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BMO upgrades BioMarin to “strong buy.” The upgrade follows BMO’s recent initiation of coverage with an “outperform” rating and a $98 price target, implying substantial upside from the current trading level. BMO upgrades BioMarin to strong buy
• Positive Sentiment: Alesta acquisition expands BioMarin’s rare-disease pipeline. BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, with up to $215 million in milestone payments. The deal adds ALE1, an oral treatment candidate for hypophosphatasia, a rare genetic bone disorder, and could strengthen the company’s long-term growth prospects if development and regulatory milestones are achieved. BioMarin Alesta acquisition
• Positive Sentiment: Recent operating results were stronger than expected. BioMarin’s latest reported quarter exceeded consensus earnings and revenue estimates, with revenue increasing 20% year over year. Articles from Barclays and Piper Sandler also point to potential share-price appreciation. BioMarin Q2 results benchmarking
• Neutral Sentiment: The Alesta opportunity remains early stage. ALE1 is still in clinical development, meaning the potential commercial benefit is several years away and depends on successful trials, approvals and milestone execution. The transaction therefore adds strategic potential but also development risk. BioMarin to acquire Alesta
• Negative Sentiment: Analyst opinion is not unanimous. HC Wainwright issued a pessimistic forecast, while another analyst reduced the price target to $59 despite viewing the Alesta deal favorably. This valuation disagreement may limit near-term upside and contribute to selling pressure. BioMarin analyst price target cut

BioMarin Pharmaceutical Trading Down 2.4%

NASDAQ:BMRN opened at $67.68 on Friday. BioMarin Pharmaceutical Inc. has a 52 week low of $49.26 and a 52 week high of $70.98. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The firm’s fifty day moving average is $60.45 and its 200-day moving average is $57.82. The firm has a market cap of $13.10 billion, a P/E ratio of 182.92, a P/E/G ratio of 0.50 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. The business had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. BioMarin Pharmaceutical’s quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities analysts expect that BioMarin Pharmaceutical Inc. will post 4.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BMRN has been the topic of several analyst reports. Citigroup increased their price objective on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Piper Sandler lifted their target price on BioMarin Pharmaceutical from $82.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday. Sanford C. Bernstein reduced their price target on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. Barclays increased their price target on BioMarin Pharmaceutical from $105.00 to $111.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Weiss Ratings downgraded BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a research report on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $88.83.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.